Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
Go back to Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program| (NASDAQ: ABUS) | Delayed: 5.18 +0.03 (0.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.15 | 52 Week High | $5.88 | |||
| Open | $5.10 | 52 Week Low | $2.65 | |||
| Day High | $5.20 | P/E | N/A | |||
| Day Low | $5.08 | EPS | $0.00 | |||
| Volume | 5,290,085 | |||||
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 260.10 -6.01 (2.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $266.11 | 52 Week High | $109.10 | |||
| Open | $259.00 | 52 Week Low | $31.38 | |||
| Day High | $272.08 | P/E | N/A | |||
| Day Low | $254.01 | EPS | $-1.45 | |||
| Volume | 1,998,228 | |||||
